Scott M Schuetze

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. doi request reprint Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109 5848, United States
    Eur J Cancer 48:1347-53. 2012
  2. ncbi request reprint Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy
    Scott M Schuetze
    Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    Cancer 103:339-48. 2005
  3. ncbi request reprint Adjuvant therapy for soft tissue sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 3:207-13. 2005
  4. ncbi request reprint Chemotherapy in the management of osteosarcoma and Ewing's sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0848, USA
    J Natl Compr Canc Netw 5:449-55. 2007
  5. ncbi request reprint Imaging and response in soft tissue sarcomas
    Scott M Schuetze
    Division of Hematology Oncology, Box 0848, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0848, USA
    Hematol Oncol Clin North Am 19:471-87, vi. 2005
  6. ncbi request reprint Utility of positron emission tomography in sarcomas
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0848, USA
    Curr Opin Oncol 18:369-73. 2006
  7. doi request reprint Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Rashmi Chugh
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 5843, USA
    Clin Cancer Res 16:4884-91. 2010
  8. pmc [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults
    Douglas S Hawkins
    Department of Pediatrics, Seattle Children s Hospital, and Department of Orthopedics, University of Washington, Seattle, Washington 98105 0371, USA
    Cancer 115:3519-25. 2009
  9. ncbi request reprint [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, 4800 Sandpoint Way, Mailstop B 6553, Seattle, WA 98105 0371, USA
    J Clin Oncol 23:8828-34. 2005
  10. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013

Detail Information

Publications29

  1. doi request reprint Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109 5848, United States
    Eur J Cancer 48:1347-53. 2012
    ..The combination of sirolimus and cyclophosphamide demonstrated synergistic anti-sarcoma activity in preclinical models; therefore, we conducted a phase II trial of sirolimus and cyclophosphamide in patients with advanced sarcoma...
  2. ncbi request reprint Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy
    Scott M Schuetze
    Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    Cancer 103:339-48. 2005
    ..Serial FDG-PET scans were taken to determine the correlation between FDG uptake and patient outcomes in patients receiving multimodality treatment of extremity sarcomas...
  3. ncbi request reprint Adjuvant therapy for soft tissue sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 3:207-13. 2005
    ....
  4. ncbi request reprint Chemotherapy in the management of osteosarcoma and Ewing's sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0848, USA
    J Natl Compr Canc Netw 5:449-55. 2007
    ..Patient participation in clinical trials of novel therapies for Ewing's sarcoma and osteosarcoma should be strongly encouraged...
  5. ncbi request reprint Imaging and response in soft tissue sarcomas
    Scott M Schuetze
    Division of Hematology Oncology, Box 0848, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0848, USA
    Hematol Oncol Clin North Am 19:471-87, vi. 2005
    ..Functional imaging of soft tissue sarcomas may prove to be useful clinically, therefore further investigation is warranted...
  6. ncbi request reprint Utility of positron emission tomography in sarcomas
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0848, USA
    Curr Opin Oncol 18:369-73. 2006
    ..Recent developments in the use of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the clinical management of patients with suspected or diagnosed sarcomas are presented...
  7. doi request reprint Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Rashmi Chugh
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 5843, USA
    Clin Cancer Res 16:4884-91. 2010
    ..Here, we report specifically on the outcome of patients with AF as well as evaluations undertaken to examine the mechanism of imatinib...
  8. pmc [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults
    Douglas S Hawkins
    Department of Pediatrics, Seattle Children s Hospital, and Department of Orthopedics, University of Washington, Seattle, Washington 98105 0371, USA
    Cancer 115:3519-25. 2009
    ..To determine the prognostic value of FDG-PET response for progression-free survival (PFS) in osteosarcoma, the authors of this report reviewed the University of Washington Medical Center experience...
  9. ncbi request reprint [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, 4800 Sandpoint Way, Mailstop B 6553, Seattle, WA 98105 0371, USA
    J Clin Oncol 23:8828-34. 2005
    ..To determine the prognostic value of FDG PET response for progression-free survival (PFS) in ESFTs, we reviewed the University of Washington Medical Center experience...
  10. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
    ....
  11. doi request reprint Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation
    David R Lucas
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109 0054, USA
    Oncologist 13:451-8. 2008
    ....
  12. doi request reprint Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?
    Scott M Schuetze
    University of Michigan, C342 Med Inn, SPC 5848, 1500 E Medical Center Drive, Ann Arbor, Michigan, 48109 5848, USA
    Oncologist 14:1003-12. 2009
    ..In the absence of conclusive results from an adequately powered, randomized, controlled clinical trial, the available data support the use of chemotherapy in the management of high-risk, localized, soft tissue sarcoma...
  13. ncbi request reprint Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication
    Mikelle D Bassett
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Cancer 103:409-16. 2005
    ..The authors examined their single institutional experience and correlated their classification with clinical features and outcome...
  14. doi request reprint Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results
    Binu Malhotra
    Division of Hematology Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    Curr Opin Oncol 24:419-24. 2012
    ..Given its rarity, and paucity of randomized trials, the nuances of treatment are not widely understood. In this review we attempt to summarize the available data to guide treatment choices for physicians managing this disease...
  15. doi request reprint Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options
    Megan V Caram
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Michigan, USA
    J Surg Oncol 104:888-95. 2011
    ....
  16. doi request reprint Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology
    Eun Young Karen Choi
    Departments of Pathology Internal Medicine Orthopedic Surgery, University of Michigan, Ann Arbor, MI
    Am J Surg Pathol 37:1379-86. 2013
    ..8 months. CIC-DUX4 sarcoma represents a novel translocation-associated sarcoma with distinctive histopathologic features and rapid disease progression. ..
  17. doi request reprint Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint
    Lili Zhao
    Biostatistics Unit, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Stat Med 31:1804-20. 2012
    ..An example based on a recently conducted phase II sarcoma trial illustrates the method...
  18. pmc Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  19. doi request reprint Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors
    Hussein Tawbi
    Department of, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Oncologist 13:459-66. 2008
    ..The present study extends that work to examine the expression of EGFR in MPNSTs and the characterization of potential targets of the EGFR tyrosine kinase domain...
  20. doi request reprint Selection of response criteria for clinical trials of sarcoma treatment
    Scott M Schuetze
    Department of Internal Medicine, Division of Hematology Oncology, 1500 E Medical Center Drive, C409 MIB, Ann Arbor, Michigan 48109 5843, USA
    Oncologist 13:32-40. 2008
    ....
  21. ncbi request reprint So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity
    Anthony Chang
    Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Int J Surg Pathol 13:185-95. 2005
    ..In addition, 2 of the 3 cases developed distant metastases to the lungs, which suggests that these lesions may have a worse prognosis than previously believed...
  22. doi request reprint Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors
    R Grant Rowe
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 5848, USA
    Urology 81:347-53. 2013
    ..To evaluate our own experience with primary Ewing sarcoma family tumors (ESFTs) of the kidney and to review cases of this in published reports...
  23. doi request reprint Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors
    Ann W Silk
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Curr Treat Options Oncol 13:285-98. 2012
    ..Participation in clinical trials, when available, is highly encouraged...
  24. ncbi request reprint Chordoma: the nonsarcoma primary bone tumor
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, 24 Frank Lloyd Wright Drive, A3400, P O Box 483, Ann Arbor, Michigan 48106, USA
    Oncologist 12:1344-50. 2007
    ..Radiation therapy may also salvage some patients with local recurrence. One series reported a 2-year actuarial local control rate of 33% for patients treated with proton beam irradiation...
  25. ncbi request reprint Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans
    Brian P Rubin
    Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    J Clin Oncol 20:3586-91. 2002
    ..We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate...
  26. ncbi request reprint Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
    ..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel...
  27. doi request reprint New targets for therapy of sarcoma
    John M Magenau
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Curr Opin Oncol 20:400-6. 2008
    ..Systemic treatment options for advanced sarcoma remain limited. Emerging trends exploring targeted therapy for the treatment of sarcoma are reviewed here...
  28. ncbi request reprint Targeted therapy for dermatofibrosarcoma protuberans
    Thomas A Abrams
    Division of Hematology Oncology, Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0848, USA
    Curr Oncol Rep 8:291-6. 2006
    ..Three phase II, multicenter clinical trials are open to further investigate the role of imatinib mesylate in DFSP...
  29. ncbi request reprint Fluorodeoxyglucose positron emission tomography scanning: basic principles and imaging of adult soft-tissue sarcomas
    Ernest U Conrad
    Department of Orthopaedics and Sports Medicine, University of Washington, Seattle 98195 6500, USA
    J Bone Joint Surg Am 86:98-104. 2004